These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20737218)

  • 1. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy.
    Evans DB; Erickson BA; Ritch P
    Ann Surg Oncol; 2010 Nov; 17(11):2803-5. PubMed ID: 20737218
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in the management of borderline resectable pancreatic cancer.
    Sharma J; Ng J; Goodman MD; Saif MW
    JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining venous involvement in borderline resectable pancreatic cancer.
    Chun YS; Milestone BN; Watson JC; Cohen SJ; Burtness B; Engstrom PF; Haluszka O; Tokar JL; Hall MJ; Denlinger CS; Astsaturov I; Hoffman JP
    Ann Surg Oncol; 2010 Nov; 17(11):2832-8. PubMed ID: 20725860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy in resectable pancreatic cancer.
    Irmscher S; Senninger N; Schleicher C
    Ann Surg Oncol; 2008 Jul; 15(7):2059-60; author reply 2061. PubMed ID: 18266042
    [No Abstract]   [Full Text] [Related]  

  • 10. Endoscopic ultrasound-guided fine-needle aspiration can lead to nonresectability of pancreatic cancer due to severe biopsy-induced inflammation.
    Dahl S; Mortensen MB
    Endoscopy; 2008 Sep; 40 Suppl 2():E96. PubMed ID: 19085713
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
    Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
    Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy.
    Sperti C; Pasquali C; Pastorelli D; Ferronato A; Decet G; Pedrazzoli S
    Acta Biomed; 2003; 74 Suppl 2():91-5. PubMed ID: 15055044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodality management of localized pancreatic cancer.
    Wayne JD; Wolff RA; Pisters PW; Evans DB
    Cancer J; 2001; 7 Suppl 1():S35-46. PubMed ID: 11504284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
    Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
    Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant therapy in pancreatic cancer].
    Ji JF; Li ZY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):644-7. PubMed ID: 16274051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant therapy may allow unresectable tumors becoming resectable].
    Sa Cunha A
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S113-6. PubMed ID: 26118869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
    Carr JA; Ajlouni M; Wollner I; Wong D; Velanovich V
    Am Surg; 1999 Dec; 65(12):1143-9. PubMed ID: 10597062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatment for resectable pancreatic cancer.
    Chua YJ; Cunningham D
    J Clin Oncol; 2005 Jul; 23(20):4532-7. PubMed ID: 16002844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.